Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 1
2007 1
2015 1
2016 1
2017 1
2018 4
2019 3
2020 5
2021 6
2022 2
2023 2
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
Slootbeek PHJ, Luna-Velez MV, Privé BM, van der Doelen MJ, Kloots ISH, Pamidimarri Naga S, Onstenk HE, Nagarajah J, Westdorp H, van Oort IM, Kroeze LI, Schalken JA, Bloemendal HJ, Mehra N. Slootbeek PHJ, et al. Among authors: van der doelen mj. Theranostics. 2024 Aug 1;14(12):4555-4569. doi: 10.7150/thno.96322. eCollection 2024. Theranostics. 2024. PMID: 39239510 Free PMC article.
Metabolism-mediated cytotoxicity of ochratoxin A.
Simarro Doorten AY, Bull S, van der Doelen MA, Fink-Gremmels J. Simarro Doorten AY, et al. Among authors: van der doelen ma. Toxicol In Vitro. 2004 Jun;18(3):271-7. doi: 10.1016/j.tiv.2003.10.001. Toxicol In Vitro. 2004. PMID: 15046773
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
van der Doelen MJ, Oving IM, Wyndaele DNJ, van Basten JP, Terheggen F, van de Luijtgaarden ACM, Oyen WJG, van Schelven WD, van den Berkmortel F, Mehra N, Janssen MJR, Prins JB, Gerritsen WR, Custers JAE, van Oort IM. van der Doelen MJ, et al. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):142-150. doi: 10.1038/s41391-022-00569-8. Epub 2022 Jul 8. Prostate Cancer Prostatic Dis. 2023. PMID: 35804188 Free PMC article.
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Kuppen MC, Westgeest HM, van der Doelen MJ, van den Eertwegh AJ, Coenen JL, Aben KK, van den Bergh AC, Bergman AM, den Bosch JV, Celik F, Hendriks MP, Lavalaye J, der Meer SV, Polee MB, Somford DM, van Oort IM, Uyl-de Groot CA, Gerritsen WR. Kuppen MC, et al. Among authors: van der doelen mj. Future Oncol. 2020 Jul;16(19):1371-1384. doi: 10.2217/fon-2020-0039. Epub 2020 May 29. Future Oncol. 2020. PMID: 32469606
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Privé BM, Slootbeek PHJ, Laarhuis BI, Naga SP, van der Doelen MJ, van Kalmthout LWM, de Keizer B, Ezziddin S, Kratochwil C, Morgenstern A, Bruchertseifer F, Ligtenberg MJL, Witjes JA, van Oort IM, Gotthardt M, Heskamp S, Janssen MJR, Gerritsen WR, Nagarajah J, Mehra N. Privé BM, et al. Among authors: van der doelen mj. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):71-78. doi: 10.1038/s41391-021-00424-2. Epub 2021 Jul 12. Prostate Cancer Prostatic Dis. 2022. PMID: 34253846
Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC.
Laarhuis BI, Janssen MJR, Simons M, van Kalmthout LWM, van der Doelen MJ, Peters SMB, Westdorp H, van Oort IM, Litjens G, Gotthardt M, Nagarajah J, Mehra N, Privé BM. Laarhuis BI, et al. Among authors: van der doelen mj. Clin Genitourin Cancer. 2023 Oct;21(5):e352-e361. doi: 10.1016/j.clgc.2023.04.003. Epub 2023 Apr 21. Clin Genitourin Cancer. 2023. PMID: 37164814 Free article.
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ, Duizer ML, van der Doelen MJ, Kloots ISH, Kuppen MCP, Westgeest HM, Uyl-de Groot CA, Pamidimarri Naga S, Ligtenberg MJL, van Oort IM, Gerritsen WR, Schalken JA, Kroeze LI, Bloemendal HJ, Mehra N. Slootbeek PHJ, et al. Among authors: van der doelen mj. Int J Cancer. 2021 Jan 15;148(2):385-395. doi: 10.1002/ijc.33306. Epub 2020 Oct 3. Int J Cancer. 2021. PMID: 32965028 Free PMC article.
24 results